Torrent Pharmaceuticals Ltd

- No explicit mention of any new fundraising through debt or equity in the current quarter or near future. - Sudhir Menon indicated that the company expects to become net cash positive by H1 FY27 due to ongoing repayments. - Interest expenses are expected to continue decreasing quarter-on-quarter because of these repayments. - Discussions on capital allocation priorities are still a work in progress, with more clarity expected in a couple of quarters. - The company prioritizes investments in India branded generics, followed by selective opportunities in international developed markets. - No specific plans or announcements regarding raising fresh debt or equity were disclosed during the call.

- Sudhir Menon mentioned that the company's capital allocation priorities and strategic investments are still a work in progress, with specific details expected in a couple of quarters. - The top priority for capital allocation remains India, especially branded generics, where the company has the best track record and highest comfort. - They remain open to opportunities in developed markets like Germany and the US in specified areas. - There was mention of reinvestment happening in the branded business which could impact margin improvements, indicating ongoing or planned investments. - The company is also making investments in market formation activities such as information dissemination and education for new product launches. - No specific new capex or strategic transaction details were disclosed at this stage.

- India business continues to outperform market growth with 12-13% revenue growth YTD; focus on cardiac, diabetes, and gastro drives growth. - Chronic business in India grew 14% vs. IPM 10%, aided by new product launches and expanded field force. - Brazil market expected to maintain double-digit growth (~10-12% constant currency); government price hikes anticipated to offset currency depreciation. - Germany business to see growth from new tenders starting Q2 next year; expect continued high single-digit growth. - US business stable but slow pickup expected short-term; growth dependent on new ANDA filings. - Overall, company projects 7% underlying revenue growth normalized for insulin business and currency impact in Q3. - Operating EBITDA margin expected to improve 50-100 bps annually, supported by branded business growth and US launches next year. - Insulin business expected to recover with Q4 showing spillover above Rs. 75-80 crore quarterly run rate.

- Operating EBITDA margin expected to sustain at about 32.5% in Q4 FY25. - Full year FY25 operating EBITDA margin is anticipated to improve to around 32.5% from 31.4% last year (110 bps improvement). - Margin improvement guidance of 50 to 100 basis points per year expected to continue going forward. - FY26 margin to improve by 50 to 100 bps, driven by branded segment contribution and expected US launches reducing negative contribution. - Insulin business expected to return to normal run rate (Rs. 75-80 crore per quarter) plus spillover revenue in Q4. - Brazil to continue double-digit constant currency growth with expected government price revisions in April 2025. - India branded business to continue outperforming market growth (~12-13% YTD) with focus on cardiac, diabetes, gastro. - Net debt to EBITDA expected to reduce, with company likely to turn net cash positive by first half FY27.

- The document does not explicitly mention the current or expected order book or pending orders for Torrent Pharmaceuticals. - However, highlights on product launches and market expectations are noted: - In Brazil and India, plans to launch GLP-1 products are aligned with patent expiry in March 2026, aiming to be in the first wave of launches. - Brazil has a rich pipeline of 20 molecules filed and awaiting ANVISA approval. - Germany business won incremental new tenders starting to contribute from Q2 FY26. - Focus remains on market formation activities and education for new products, indicating pipeline and upcoming opportunities. - No specific quantitative data on order book or pending orders provided during the Q3 FY25 call.